Atrial Fibrillation Market Report 2025 (Global Edition)

Global Atrial Fibrillation Market Report 2025 Market Size Split by Type (Surgical, Non-Surgical, Pharmacological Drugs), by Technology (Radiofrequency, Laser, Cryotherapy, Others), by End-user (Hospit...

Atrial Fibrillation Market Report Description

We have various report editions of Atrial Fibrillation Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Impact of Tariff Trumph on Pharmaceuticals Industry

The reintroduction of tariffs under President Trump’s “Liberation Day Tariffs” in April 2025 has created significant disruption in global pharmaceutical trade. These tariffs, ranging from 10% to 46%, specifically target pharmaceutical products, APIs (active pharmaceutical ingredients), medical packaging, and machinery from key manufacturers in China and India. This has led to increased production costs, supply chain delays, and regulatory challenges for U.S.-based pharmaceutical companies.

The tariffs have particularly impacted generic drug manufacturers, who rely heavily on APIs from China and India. Biopharmaceuticals and vaccines are also feeling the pressure, with tariffs on critical materials like bioproduction media and cold-chain packaging raising costs by up to 25%. Similarly, contract manufacturing organizations (CMOs) are grappling with the need to identify new suppliers and adjust production plans to mitigate rising costs.

Foreign governments, including the European Union, have retaliated with tariffs on U.S. pharmaceutical exports, further complicating global trade. Clinical trials are also impacted, as tariffs on drugs and diagnostic kits delay trial timelines.

Market research is increasingly crucial for navigating these challenges. By providing real-time data on API pricing, supplier reliability, and tariff impact, pharmaceutical firms can make informed decisions on sourcing, compliance, and investment strategies. This data-driven approach helps mitigate risks, optimize supply chains, and identify alternative manufacturing hubs to offset tariff-related disruptions.

Overall, market research is essential for pharmaceutical companies to adapt to the new tariff landscape, enabling them to maintain competitive advantage and navigate global trade dynamics effectively.

Atrial Fibrillation Market Insights Video

Competitive Landscape of the Atrial Fibrillation Market

The competitive landscape of the Atrial Fibrillation market is characterized by a diverse range of players competing to gain market share through product innovation, strategic partnerships, and aggressive marketing efforts. Key players in the market include established manufacturers, specialized Atrial Fibrillation companies, and emerging start-ups aiming to disrupt the market with innovative solutions.

September 2019: iRhythm Technologies, Inc. announced a collaboration with Verily, an Alphabet company, to develop solutions aimed at improving the screening, diagnosis, and management of atrial fibrillation (AFib) patients. (Source: https://www.irhythmtech.com/company/press-releases/irhythm-announces-collaboration-with-verily-to-develop-health-management-solutions-for-atrial-fibrillation-patients#:~:text=SAN%20FRANCISCO%2C%20September%204%2C%202019,with%20atrial%20fibrillation%20(AFib). )

Top Companies Market Share in Atrial Fibrillation Industry: (In no particular order of Rank)

• Abbott (US)
• Johnson & Johnson Private Limited (U.S.)
• MicroPort Scientific Corporation. (China)
• Boston Scientific Corporation (US).
• Medtronic (US)
• BIOTRONIK SE & Co. KG (US)
• Koninklijke Philips N.V. (Netherlands)
• Siemens (US)
• AtriCure
• Inc (US)
• Sanofi (US)
• Biosense Webster
• Inc (US)
• CardioFocus. (US)
• BRISTOL-MYERS SQUIBB COMPANY (US)
• Boehringer Ingelheim International GmbH. (US)
• GENERAL ELECTRIC COMPANY (US)
• Pfizer Inc. (US)
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Atrial Fibrillation Market

Which Region Dominates the Atrial Fibrillation Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024. It accounted for around 40% of the global revenue. North America, particularly the United States, experiences a high prevalence of atrial fibrillation and other cardiovascular diseases. Contributing factors include an aging population, sedentary lifestyles, high obesity rates, and widespread conditions such as hypertension and diabetes. The number of Americans aged 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050, a 47% increase, with this age group’s share of the total population rising from 17% to 23%. In 2021, among U.S. adults aged 18 years or older, 97.6 million—more than one in three—had prediabetes. This includes 32.8 million adults aged 18 to 44, 37.5 million adults aged 45 to 64, and 27.2 million adults aged 65 or older. This large patient population drives the demand for AF-related treatments and services.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the Atrial Fibrillation market due to several compelling reasons. ? The prevalence of atrial fibrillation is rising in the Asia Pacific region, primarily due to an aging population and the increasing burden of cardiovascular diseases. Countries such as China, Japan, and India have substantial elderly populations that are more prone to AF. According to a report by the United Nations Population Fund and the International Institute for Population Sciences, India's elderly population is expected to double to 20.8% by 2050 and reach 36% by the end of the century. This demographic shift towards an older population significantly contributes to the growing incidence of AF in the region.

 

The current report Scope analyzes Atrial Fibrillation Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Switzerland, Luxembourg, Rest of Europe)
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Taiwan, South East Asia, Rest of APAC)
• Latin America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East (Saudi Arabia, Turkey, UAE, Egypt, Qatar, Rest of Middle East)
• Africa (Nigeria, South Africa, Rest of Africa)

The above graph is for illustrative purposes only.

North America Atrial Fibrillation Market Analysis

According to Cognitive Market Research, the global Atrial Fibrillation market size was estimated at USD 10584.2 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 4233.6 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Atrial Fibrillation market with a market size of USD 3340.3 million in 2024 and is projected to grow at a CAGR of 4.5% during the forecast period. The demand is amplified by the nation's Advanced Healthcare Infrastructure.
• The Canada Atrial Fibrillation market had a market share of USD 508.0 million in 2024 and is projected to grow at a CAGR of 5.5% during the forecast period. Canada's Well-Established Pharmaceutical and Medical Device Industry to increased usage of Atrial Fibrillation.
• The Mexico Atrial Fibrillation market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 385.2 million in 2024.

Europe Atrial Fibrillation Market Analysis

According to Cognitive Market Research, the global Atrial Fibrillation market size was estimated at USD 10584.2 Million out of which Europe held the market of more than 30% of the global revenue with a market size of USD 3175.2 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.0% from 2024 to 2031.

• The United Kingdom Atrial Fibrillation market had a market share of USD 533.4 million in 2024 and is projected to grow at a CAGR of 5.8% during the forecast period. In the UK, Atrial Fibrillation sales witness an upswing due to the nation's highly developed healthcare infrastructure with state-of-the-art medical facilities, specialized electrophysiology labs, and advanced diagnostic and treatment technologies.
• The France Atrial Fibrillation market is projected to witness growth at a CAGR of 4.2% during the forecast period, with a market size of USD 292.1 million in 2024.
• According to Cognitive Market Research, the Germany Atrial Fibrillation market size was valued at USD 628.7 million in 2024 and is projected to grow at a CAGR of 5.2% during the forecast period. In Germany, Atrial Fibrillation sales surged due to the rapid increase in cardiac diseases in aging population.
• The Italy Atrial Fibrillation market is projected to witness growth at a CAGR of 4.4% during the forecast period, with a market size of USD 273.0 million in 2024.
• The Russia Atrial Fibrillation market is projected to witness growth at a CAGR of 4.0% during the forecast period, with a market size of USD 492.1 million in 2024.
• The Spain Atrial Fibrillation market is projected to witness growth at a CAGR of 4.1% during the forecast period with a market size of USD 260.3 million in 2024
• The Luxembourg Atrial Fibrillation market is projected to witness growth at a CAGR of 5.1% during the forecast period, with a market size of USD 98.4 million in 2024.
• The Portugal Atrial Fibrillation market is projected to witness growth at a CAGR of 4.8% during the forecast period, with a market size of USD 66.6 million in 2024.
• The Greece Atrial Fibrillation market is projected to witness growth at a CAGR of 5.3% during the forecast period, with a market size of USD 38.1 million in 2024.
• Rest of Europe's Atrial Fibrillation market is projected to witness growth at a CAGR of 3.7% during the forecast period, with a market size of USD 492.1 million in 2024.

Asia Pacific Atrial Fibrillation Market Analysis

According to Cognitive Market Research, the global Atrial Fibrillation market size was estimated at USD 10584.2 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 2434.3 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.

• According to Cognitive Market Research, the China Atrial Fibrillation market size was valued at USD 1095.4 million in 2024 and is projected to grow at a CAGR of 8.0% during the forecast period. Atrial Fibrillation sales surge in China due to the demographic shift towards an older population significantly contributes to the rising incidence of AF.
• The Japan Atrial Fibrillation market is projected to witness growth at a CAGR of 7.0% during the forecast period, with a market size of USD 335.9 million in 2024.
• The India Atrial Fibrillation market had a market share of USD 292.1 million in 2024 and is projected to grow at a CAGR of 10.3% during the forecast period. India's growing awareness of AF and its consequences among patients, caregivers, and healthcare professionals, drive the market.
• The South Korea Atrial Fibrillation market is projected to witness growth at a CAGR of 7.6% during the forecast period, with a market size of USD 243.4 million in 2024.
• The Australia Atrial Fibrillation market is projected to witness growth at a CAGR of 8.2% during the forecast period, with a market size of USD 126.5 million in 2024.
• The South East Asia Atrial Fibrillation market is projected to witness growth at a CAGR of 9.5% during the forecast period, with a market size of USD 167.9 million in 2024.
• The Rest of Asia Pacific Atrial Fibrillation market is projected to witness growth at a CAGR of 8.3% during the forecast period, with a market size of USD 172.8 million in 2024.

South America Atrial Fibrillation Market Analysis

According to Cognitive Market Research, the global Atrial Fibrillation market size was estimated at USD 10584.2 Million out of which Latin America market of more than 5% of the global revenue with a market size of USD 529.2 million in 2024 and will grow at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Atrial Fibrillation market size was valued at USD 226.5 million in 2024 and is projected to grow at a CAGR of 6.5% during the forecast period. Atrial Fibrillation sales flourish in Brazil due to the healthcare policies and regulations to improve the quality of care and patient outcomes.
• Argentina Atrial Fibrillation market had a market share of USD 88.9 million in 2024 and is projected to grow at a CAGR of 6.8% during the forecast period. Argentina's growing investments in healthcare infrastructure, workforce training, and medical research, drive the market.
• Colombia Atrial Fibrillation market is projected to witness growth at a CAGR of 5.7% during the forecast period with a market size of USD 47.1 million in 2024.
• Peru Atrial Fibrillation market is projected to witness growth at a CAGR of 6.1% during the forecast period with a market size of USD 43.4 million in 2024.
• Chile Atrial Fibrillation market is projected to witness growth at a CAGR of 6.2% during the forecast period with a market size of USD 38.1 million in 2024.
• The Rest of Latin America Atrial Fibrillation market is projected to witness growth at a CAGR of 5.0% during the forecast period, with a market size of USD 85.2 million in 2024.

Middle East Atrial Fibrillation Market Analysis

According to Cognitive Market Research, the global Atrial Fibrillation market size was estimated at USD 10584.2 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 211.6 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.

• The GCC Countries Atrial Fibrillation market is projected to witness growth at a CAGR of 7.0% during the forecast period with a market size of USD 90.6 million in 2024. Atrial Fibrillation sales flourish due to government initiatives to support healthcare and strong economic growth.
• The Egypt Atrial Fibrillation market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 22.2 million in 2024.
• The South Africa Atrial Fibrillation market is projected to witness growth at a CAGR of 7.2% during the forecast period, with a market size of USD 33.4 million in 2024. Atrial Fibrillation sales flourish in South Africa due to the rising consumer awareness of health issues, and improved disease management.
• The Turkey Atrial Fibrillation market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 18.2 million in 2024.
• The Nigeria Atrial Fibrillation market is projected to witness growth at a CAGR of 5.3% during the forecast period, with a market size of USD 22.2 million in 2024.
• The Rest of the MEA Atrial Fibrillation market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 24.9 million in 2024.

Atrial Fibrillation Market Analysis

Atrial Fibrillation Market Type Segment Analysis

According to Cognitive Market Research, Surgical type stands out as the dominating category. Surgical interventions for atrial fibrillation, including catheter ablation and maze procedures, have demonstrated high success rates in restoring normal heart rhythm and preventing AF recurrence. These procedures are often more effective than pharmacological treatments, especially in patients with persistent or long-standing persistent AF. This superior efficacy drives the demand and market dominance of surgical treatments.

Pharmacological Drugs emerge as the fastest-growing category in the Atrial Fibrillation market. Pharmacological drugs are typically the first-line treatment for atrial fibrillation. Medications such as anticoagulants, antiarrhythmics, beta-blockers, and calcium channel blockers are prescribed to manage heart rate, maintain sinus rhythm, and prevent thromboembolic events. The widespread initial use of these drugs significantly contributes to their dominance in the market.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Atrial Fibrillation Industry. Request a Free Sample PDF!

Atrial Fibrillation Market technology Segment Analysis

According to Cognitive Market Research, the dominating technology is Radiofrequency. Radiofrequency ablation is extensively researched and clinically validated as an effective treatment for atrial fibrillation. This procedure entails delivering controlled radiofrequency energy to targeted areas of the heart, resulting in the formation of scar tissue that interrupts abnormal electrical pathways causing AF. Multiple studies have consistently reported high success rates in restoring sinus rhythm and reducing AF recurrence with radiofrequency ablation, establishing it as the preferred option for many patients and healthcare providers.

The fastest-growing technology in the Atrial Fibrillation market is Cryotherapy. Cryotherapy, particularly cryoablation, has demonstrated notable safety and efficacy in managing atrial fibrillation. Cryoablation employs extreme cold temperatures to create scar tissue and disrupt irregular electrical pathways in the heart. Clinical investigations have affirmed that cryoablation effectively restores normal heart rhythm while minimizing the occurrence of complications. Consequently, cryoablation is favored by both patients and healthcare providers as an alternative treatment option for atrial fibrillation.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Atrial Fibrillation End-user Segment Analysis

According to Cognitive Market Research, the dominating End user is Hospitals. Hospitals are equipped with sophisticated medical infrastructure, including specialized electrophysiology labs that feature cutting-edge cardiac mapping systems, ablation catheters, and monitoring devices. This infrastructure enables hospitals to provide a comprehensive array of diagnostic and treatment services for atrial fibrillation (AF), ranging from catheter ablation to surgical interventions and implantable device therapies. The availability of advanced equipment and facilities positions hospitals as the preferred choice for managing complex AF cases.

The fastest-growing End user in the Atrial Fibrillation market is Specialty Clinics. Specialty clinics, focusing solely on cardiology or electrophysiology, boast a heightened level of expertise and specialization in AF management compared to general healthcare facilities. Cardiologists and electrophysiologists at these clinics possess extensive training and hands-on experience in diagnosing and treating arrhythmias, including AF. Their specialized knowledge enables them to deliver personalized and thorough care to patients with AF, ensuring optimal treatment outcomes.

• Hospitals
• Specialty Clinics
• Others

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion